{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "EOLS", "name": "Evolus, Inc.", "url": "https://frontierpicks.com/dossiers/EOLS/", "json_url": "https://frontierpicks.com/dossiers/EOLS.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a7", "n": 7 }, "current_thesis": "Evolus’s margin-led re-rating failed its published $8.00 weekly price test at the $7.84 close on 2026-09-11. The business case remains subject to delivery of management’s 2026 revenue guidance of $330–337 million and adjusted gross margin guidance of 67.0–67.5%.", "invalidation_trigger": "A weekly close below $8.00 ends the published September extension thesis; this condition was met on 2026-09-11 at $7.84. The threshold remains unchanged to preserve the recorded outcome.", "catalyst_date": "2026-09-29", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics", "medtech-diagnostics" ], "tags": [], "sources": [], "notes": [ "Jeuveau drug substance is manufactured in South Korea by Daewoong; the 15% Section 232 rate on Korea-origin patented pharma flows into landed cost.", "A Form S-3 universal shelf for up to $250M of common, preferred, debt, warrants, units and rights is on file — issuance needs no new registration.", "Evolus reports adjusted EBITDA and non-GAAP opex alongside GAAP; in Q2 2026 adjusted EBITDA was positive while adjusted EPS missed consensus.", "Small cap: market capitalisation $527.74M as of 2026-08-11 with institutional ownership 90.69%, so single prints and index-level risk appetite dominate the tape.", "CEO David Moatazedi also serves as a company director, so his Form 4 filings cover both officer and director capacity." ], "body_markdown": "## Current Thesis\n\nEvolus’s margin-led re-rating has failed its published price test: the 2026-09-11 weekly close of $7.84 breached the $8.00 threshold established in the September 5 research note. The underlying business case remains measurable against management’s 2026 revenue guidance of $330–337 million and adjusted gross margin guidance of 67.0–67.5%, issued on August 5. [Company results](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-Strong-Second-Quarter-2026-Financial-Results-Delivers-Third-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Raises-Full-Year-2026-Financial-Outlook/default.aspx)\n\nAs a judgment about the previously published September extension, the narrative is dead — the September 11 close crossed its stated invalidation before the September 29 tariff catalyst. This is a finding about the market structure; the supplied September 11 price observations do not establish a deterioration in company revenue.\n\n## Bull Case\n\n- **Revenue growth supports the business case.** Evolus reported second-quarter revenue of $84.1 million, up 21% year over year, on 2026-08-05. Management raised the lower end of its annual revenue outlook. [Company results](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-Strong-Second-Quarter-2026-Financial-Results-Delivers-Third-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Raises-Full-Year-2026-Financial-Outlook/default.aspx)\n- **Operating improvement has reported support.** Second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached $4.7 million, the third consecutive positive quarter, according to the 2026-08-05 release. That supports the margin-inflection interpretation, although this short sequence cannot establish durability. [Company results](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-Strong-Second-Quarter-2026-Financial-Results-Delivers-Third-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Raises-Full-Year-2026-Financial-Outlook/default.aspx)\n\n## Bear Case\n\n- **The published price condition fired.** The 2026-09-11 adjusted weekly close of $7.84 was below the September 5 note’s $8.00 invalidation threshold. The prior extension thesis therefore failed its stated test.\n- **Adjusted profitability needs qualification.** The 2026-08-05 release reported a second-quarter operating loss under generally accepted accounting principles of $4.5 million. The quarter’s gross margin also benefited from a tariff refund of approximately 120 basis points. [Company results](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-Strong-Second-Quarter-2026-Financial-Results-Delivers-Third-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Raises-Full-Year-2026-Financial-Outlook/default.aspx)\n\n## Setup & Price Structure\n\nThe supplied adjusted daily series places the September 11 close at $7.84, 15.7% below its $9.30 trailing-year high. The shares remained up 16.5% over three months, while the 14-period relative strength index (RSI) stood at 40.3. Those measurements describe a retreat within a positive three-month return; they do not establish a completed base.\n\nHC Wainwright maintained its $13 analyst target on 2026-08-25, according to the supplied Benzinga report. That is an observable expression of analyst optimism, not evidence of expanding participation. The September 11 observations contain no moving-average value, trading-volume comparison, short-interest measurement or retail-attention series sufficient to establish crowding.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-29 — Jeuveau tariff applicability.** Management’s 2026-05-04 earnings discussion identified a 15% South Korean pharmaceutical tariff effective on this date and left its outlook unchanged. The relevant test is whether subsequent company guidance attributes a reduction in expected margin to the duty; the calendar date alone does not establish an earnings impact. [May earnings discussion](https://www.fool.com/earnings/call-transcripts/2026/05/04/evolus-eols-q1-2026-earnings-transcript/)\n\nAs checked on 2026-09-13, the accessible company events page supplied no confirmed forthcoming earnings date. An estimated date from the earlier note is therefore not presented as a scheduled event. [Company calendar](https://investors.evolus.com/events-and-presentations/)\n\n## What Would Change Our Mind\n\nThe loss of the previously published price threshold has already broken the extension case: a weekly close below $8.00 occurred on 2026-09-11 at $7.84. A subsequent weekly close above $8.00 would establish a recovery of that threshold, without reversing the recorded invalidation.\n\nFor a renewed operating-improvement case, the concrete tests remain the revenue and adjusted-margin ranges issued on 2026-08-05. A reduction below either range would contradict that case. Maintaining guidance through the September 29 tariff date would leave it unresolved until reported results establish delivery.\n\n## Correlation Notes\n\nEvolus is treated here as a single-name aesthetics setup. Its 2026-08-05 results identify revenue from neurotoxins and injectable hyaluronic acid gels, providing a business connection to cosmetic-treatment demand. [Company results](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-Strong-Second-Quarter-2026-Financial-Results-Delivers-Third-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Raises-Full-Year-2026-Financial-Outlook/default.aspx)\n\nThe supplied September 11 observations contain no matched peer-return series. The sample is insufficient to support a statistical correlation claim or attribute the decline to a wider industry move.", "first_seen": "2026-08-13", "last_analyzed": "2026-09-17T06:03:52+00:00", "last_synthesized": "2026-09-13", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }